^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    XRD-0394

    i
    Other names: XRD-0394
    Associations

    News

    Trials
    Company:
    XRad Therap
    Drug class:
    DNA PK inhibitor, ATM kinase inhibitor
    Related drugs:
    Associations

    News

    Trials
    9ms
    A novel dual ATM/DNA-PK inhibitor, XRD-0394, potently radiosensitizes and potentiates PARP and topoisomerase I inhibitors. (PubMed, Mol Cancer Ther)
    A Phase Ia clinical trial (NCT05002140) with XRD-0394 in combination with RT has completed. These results provide a rationale for future clinical trials with XRD-0394 in combination with RT, PARP inhibitors and targeted delivery of topoisomerase I inhibitors.
    Journal
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
    |
    XRD-0394
    12ms
    Trial of XRD-0394, a Kinase Inhibitor, in Combination With Palliative Radiotherapy in Advanced Cancer Patients (clinicaltrials.gov)
    P1, N=12, Completed, XRad Therapeutics Inc | Active, not recruiting --> Completed | Trial completion date: Dec 2023 --> Jul 2023 | Trial primary completion date: Dec 2023 --> Jul 2023
    Trial completion • Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    XRD-0394
    over1year
    Trial of XRD-0394, a Kinase Inhibitor, in Combination With Palliative Radiotherapy in Advanced Cancer Patients (clinicaltrials.gov)
    P1, N=11, Active, not recruiting, XRad Therapeutics Inc | Recruiting --> Active, not recruiting | N=38 --> 11
    Enrollment closed • Enrollment change • Combination therapy • Metastases
    |
    XRD-0394